This drug induces, in glioma cells, both autophagic cell death via the inhibition of the PI3K/AKT/mTOR pathway [519] and cycle arrest in the G2/M-phase by increasing the expression of the cyclin-dependent kinase (CDK) inhibitor P21 [520]. This evidence concerns the gene MTOR and glioma.